Morgan Stanley Cyma Bay Therapeutics, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$12.63 - $24.47 $12.1 Million - $23.4 Million	956,945 New	956,945 $22.6 Million
Q4 2023 Feb 13, 2024	BUY	$12.63 - $24.47 $5.68 Million - $11 Million	449,474 Added 88.57%	956,945 $22.6 Million
Q3 2023 Nov 15, 2023	SELL	$10.86 - $17.62 $3.43 Million - $5.57 Million	-316,228 Reduced 38.39%	507,471 $7.57 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $1.26 Million - $1.85 Million	-168,682 Reduced 17.0%	823,699 $9.02 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $4.23 Million - $6.9 Million	719,302 Added 263.4%	992,381 $8.65 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $178,313 - $347,213	55,377 Added 25.44%	273,079 $1.71 Million
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $680,724 - $1.04 Million	-245,749 Reduced 53.03%	217,702 $763,000
Q2 2022 Oct 27, 2022	BUY	$1.72 - $3.39 $582,963 - $1.15 Million	338,932 Added 272.19%	463,451 $1.37 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $582,963 - $1.15 Million	338,932 Added 272.19%	463,451 $1.37 Million
Q1 2022 Oct 27, 2022	SELL	$2.77 - $3.64 $938,841 - $1.23 Million	-338,932 Reduced 73.13%	124,519 $388,000
Q1 2022 May 13, 2022	BUY	$2.77 - $3.64 $38,004 - $49,940	13,720 Added 12.38%	124,519 $388,000
Q4 2021 Feb 14, 2022	SELL	$3.23 - $4.6 $223,092 - $317,717	-69,069 Reduced 38.4%	110,799 $374,000
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $624,141 - $795,016	179,868 New	179,868 $656,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.